CA
ZBIO

CoreCap Advisors’s Zenas BioPharma ZBIO Stock Holding History

CoreCap Advisors’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$305 Buy
+12
New +$239 ﹤0.01% 2940

Other funds holding ZBIO

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
TM
Torren Management San Diego, California $197M AUM
PWA
Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return
HFS
Hughes Financial Services Herndon, Virginia $755M AUM 20.43% 1-Year Est. Return

CoreCap Advisors's ZBIO Position: Q2 2026 in Review

CoreCap Advisors opened a new position in Zenas BioPharma (ZBIO) in Q2 2026: 12 shares worth $305. The stake represents ﹤0.01% of the portfolio and ranks #2940 among its holdings.

9 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • CoreCap Advisors held 12 shares of Zenas BioPharma worth $305 as of Q2 2026.
  • Zenas BioPharma was a new CoreCap Advisors position in Q2 2026.
  • Zenas BioPharma made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #2940 holding.
  • 9 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.